Altimmune (ALT) Operating Income (2016 - 2025)
Historic Operating Income for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$20.9 million.
- Altimmune's Operating Income rose 1577.91% to -$20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.5 million, marking a year-over-year increase of 1917.91%. This contributed to the annual value of -$103.2 million for FY2024, which is 755.04% down from last year.
- Latest data reveals that Altimmune reported Operating Income of -$20.9 million as of Q3 2025, which was up 1577.91% from -$22.9 million recorded in Q2 2025.
- Altimmune's Operating Income's 5-year high stood at -$14.9 million during Q1 2021, with a 5-year trough of -$33.6 million in Q4 2023.
- Its 5-year average for Operating Income is -$23.7 million, with a median of -$23.1 million in 2022.
- Per our database at Business Quant, Altimmune's Operating Income plummeted by 12312.05% in 2021 and then surged by 2604.47% in 2024.
- Quarter analysis of 5 years shows Altimmune's Operating Income stood at -$24.0 million in 2021, then increased by 3.71% to -$23.1 million in 2022, then tumbled by 45.59% to -$33.6 million in 2023, then increased by 26.04% to -$24.9 million in 2024, then grew by 16.11% to -$20.9 million in 2025.
- Its Operating Income was -$20.9 million in Q3 2025, compared to -$22.9 million in Q2 2025 and -$21.8 million in Q1 2025.